{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:37:54Z","timestamp":1787503074916,"version":"build-2736575974"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jns.2021.120039","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T07:41:43Z","timestamp":1635147703000},"page":"120039","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Age at onset predicts outcome in aquaporin-4-IgG positive neuromyelitis optica spectrum disorder from a United Kingdom population"],"prefix":"10.1016","volume":"431","author":[{"given":"Athanasios","family":"Papathanasiou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radu","family":"Tanasescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris R.","family":"Tench","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Francisca","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smriti","family":"Bose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cris S.","family":"Constantinescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiju","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2021.120039_bb0005","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.jns.2021.120039_bb0010","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1007\/s00415-017-8445-8","article-title":"What\u2019s new in neuromyelitis optica? A short review for the clinical neurologist","volume":"264","author":"Whittam","year":"2017","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2021.120039_bb0015","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/WCO.0000000000000694","article-title":"Neuromyelitis optica spectrum disorders: still evolving and broadening","volume":"32","author":"Fujihara","year":"2019","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.jns.2021.120039_bb0020","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000110","article-title":"Aquaporin-4 autoimmunity","volume":"2","author":"Zekeridou","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jns.2021.120039_bb0025","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/WNL.0b013e3182a6cb5c","article-title":"Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica","volume":"81","author":"Jiao","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2021.120039_bb0030","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2021.120039_bb0035","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1177\/1352458515572406","article-title":"Demographic and clinical features of neuromyelitis optica\u202f: a review","volume":"21","author":"Pandit","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2021.120039_bb0040","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1177\/1352458513515085","article-title":"Characterization of neuromyelitis optica and neuromyelitis optic spectrum disorder patients with a late onset","volume":"20","author":"Collongues","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2021.120039_bb0045","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/brain\/awz054","article-title":"Outcome prediction models in AQP4-IgG positive neuromyelitis optic spectrum disorders","volume":"142","author":"Palace","year":"2019","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.jns.2021.120039_bb0050","doi-asserted-by":"crossref","first-page":"e607","DOI":"10.1212\/NXI.0000000000000607","article-title":"Late-onset neuromyelitis optica spectrum disorder. The importance of autoantibody serostatus","volume":"6","author":"Sepulveda","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.jns.2021.120039_bb0055","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1007\/s00415-020-09699-2","article-title":"Clinical features and prognosis of late-onset neuromyelitis optica spectrum disorders in a Latin American cohort","volume":"267","author":"Contentti","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2021.120039_bb0060","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2021.120039_bb0065","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12883-015-0417-y","article-title":"Late-onset neuromyelitis optic spectrum disorder in AQP4-seropositive patients in a Chinese population","volume":"15","author":"Mao","year":"2015","journal-title":"BMC Neurol."},{"issue":"9","key":"10.1016\/j.jns.2021.120039_bb0070","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1136\/jnnp-2015-312601","article-title":"Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica","volume":"87","author":"Waters","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"12","key":"10.1016\/j.jns.2021.120039_bb0075","doi-asserted-by":"crossref","DOI":"10.18637\/jss.v081.i12","article-title":"icenReg: regression models for interval censored data in R","volume":"81","author":"Anderson-Bergman","year":"2017","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.jns.2021.120039_bb0080","first-page":"334","article-title":"Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: a multicenter retrospective study in Korea","volume":"127","author":"Seok","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2021.120039_bb0085","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.jns.2021.120039_bb0090","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/jnnp-2011-300403","article-title":"Clinical features of neuromyelitis optica in a large Japanese cohort: comparisons between phenotypes","volume":"82","author":"Nagaishi","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2021.120039_bb0095","doi-asserted-by":"crossref","first-page":"101413","DOI":"10.1016\/j.msard.2019.101413","article-title":"Long-term outcome and prognosis in patients with neuromyelitis optica spectrum disorder from Serbia","volume":"36","author":"Drulovic","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.jns.2021.120039_bb0100","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1177\/1352458520981736","article-title":"Early age of onset predicts severity of visual impairment in patients with neuromyelitis optica spectrum disorder","volume":"27","author":"Macaron","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2021.120039_bb0105","doi-asserted-by":"crossref","first-page":"102515","DOI":"10.1016\/j.msard.2020.102515","article-title":"Clinical characteristics of very late-onset neuromyelitis optica spectrum disorder","volume":"46","author":"Cai","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.jns.2021.120039_bb0110","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1080\/00207454.2016.1254630","article-title":"Distinctive characteristics of early-onset and late-onset neuromyelitis optica spectrum disorders","volume":"127","author":"Zhang","year":"2017","journal-title":"Int. J. Neurosci."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21027416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21027416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:57:24Z","timestamp":1758383844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X21027416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":22,"alternative-id":["S0022510X21027416"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2021.120039","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Age at onset predicts outcome in aquaporin-4-IgG positive neuromyelitis optica spectrum disorder from a United Kingdom population","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2021.120039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"120039"}}